Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double Blind, Parallel-controlled, Randomised Study to Evaluate the Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine in Healthy Children 2 Months to 5 Years of Age

NCT02560272 is registered in ClinicalTrials.gov with Beijing Minhai Biotechnology Co., Ltd as lead sponsor.

NCT NCT02560272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02560272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double Blind, Parallel-controlled, Randomised Study to Evaluate the Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine in Healthy Children 2 Months to 5 Years of Age
Lead sponsor
Beijing Minhai Biotechnology Co., Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2014
Completion date
June 30, 2016
Enrollment
1,560 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

haemophilus influenzae type b infections